A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.

Trial Details

NCT ID
NCT06307925
Phase
PHASE1
Sponsor
HC Biopharma Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • HC010
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntary participation in this clinical trial, understanding and following the research protocol, and voluntarily signing the Informed Consent For…
  • Age ≥18 and ≤75, male or female.
  • Participants with histologically or cytologically confirmed diagnosis of advanced solid tumors who have failed standard therapy or for whom no stan…
  • Participants must have at least one measurable lesion according to RECIST Version1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →